Related Experiment Video
Updated: Jul 2, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Cholesterol and COVID-19-therapeutic opportunities at the host/virus interface during cell entry
Thomas Grewal1, Mai Khanh Linh Nguyen1, Christa Buechler2
1School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Abstract:
The rapid development of vaccines to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has been critical to reduce the severity of COVID-19. However, the continuous emergence of new SARS-CoV-2 subtypes highlights the need to develop additional approaches that oppose viral infections. Targeting host factors that support virus entry, replication, and propagation provide opportunities to lower SARS-CoV-2 infection rates and improve COVID-19 outcome. This includes cellular cholesterol, which is critical for viral spike proteins to capture the host machinery for SARS-CoV-2 cell entry. Once endocytosed, exit of SARS-CoV-2 from the late endosomal/lysosomal compartment occurs in a cholesterol-sensitive manner. In addition, effective release of new viral particles also requires cholesterol. Hence, cholesterol-lowering statins, proprotein convertase subtilisin/kexin type 9 antibodies, and ezetimibe have revealed potential to protect against COVID-19. In addition, pharmacological inhibition of cholesterol exiting late endosomes/lysosomes identified drug candidates, including antifungals, to block SARS-CoV-2 infection. This review describes the multiple roles of cholesterol at the cell surface and endolysosomes for SARS-CoV-2 entry and the potential of drugs targeting cholesterol homeostasis to reduce SARS-CoV-2 infectivity and COVID-19 disease severity.
Insights
Targeting cellular cholesterol is a promising strategy against SARS-CoV-2 infection. Drugs affecting cholesterol levels may reduce COVID-19 severity by blocking viral entry and replication.
Area of Science:
- Virology
- Cell Biology
- Pharmacology
Background:
- The emergence of SARS-CoV-2 variants necessitates novel therapeutic strategies beyond vaccines.
- Host factors, such as cellular cholesterol, play crucial roles in viral infection cycles.
Purpose of the Study:
- To review the multifaceted roles of cholesterol in SARS-CoV-2 entry and replication.
- To explore the therapeutic potential of targeting cholesterol homeostasis for COVID-19 treatment.
Main Methods:
- Literature review of studies investigating cholesterol's role in SARS-CoV-2 infection.
- Analysis of pharmacological agents targeting cholesterol pathways for antiviral activity.
Main Results:
- Cholesterol is essential for SARS-CoV-2 spike protein binding and cell entry.
- Viral exit from endosomes and new particle release are cholesterol-dependent processes.
- Statins, PCSK9 inhibitors, ezetimibe, and antifungals show potential in inhibiting SARS-CoV-2.
Conclusions:
- Cholesterol homeostasis is a critical target for developing new anti-SARS-CoV-2 therapies.
- Pharmacological interventions modulating cholesterol can reduce viral infectivity and mitigate COVID-19 severity.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Intracellular Movement of Viruses and Bacteria
Retrovirus Life Cycles
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

